Ketamine

Generic Name
Ketamine
Brand Names
Ketalar
Drug Type
Small Molecule
Chemical Formula
C13H16ClNO
CAS Number
6740-88-1
Unique Ingredient Identifier
690G0D6V8H
Background

Ketamine is an NMDA receptor antagonist with a potent anesthetic effect. It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories. It started being used for veterinary purposes in Belgium and in 1964 was proven that compared to PCP, it produced minor hallucinogenic effects and shorter psychotomimetic eff...

Indication

Ketamine is indicated as an anesthetic agent for recommended diagnostic and surgical procedures. If skeletal muscle relaxation is needed, it should be combined with a muscle relaxant. If the surgical procedure involves visceral pain, it should be supplemented with an agent that obtunds visceral pain. Ketamine can be used for induction of anesthesia prior oth...

Associated Conditions
-
Associated Therapies
General Anesthesia, Induction and Maintenance of General Anesthesia
Clinical Trials
Related News
finance.yahoo.com
·

Gate Neurosciences and Pitt commence antidepressant drug trial

Gate Neurosciences and Pitt initiate Phase II trial to assess combining apimostinel, a rapid-acting antidepressant, with Pitt's digital therapeutic ASAT to extend antidepressant effects. ASAT conditions positive self-associations, aiming to leverage a 'primed window of brain plasticity' for sustained relief in depression.
dovepress.com
·

Comparative Analysis of Hemodynamic Effects of Remimazolam and Propofol

Study compares hemodynamic effects of remimazolam + esketamine vs. propofol + esketamine in elderly patients undergoing painless colonoscopy, finding remimazolam offers superior stability, quicker recovery, and fewer adverse events like hypotension, sinus tachycardia, and sinus bradycardia, despite a longer induction time.
morningstar.com
·

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter and Year to Date 2024

NRx Pharmaceuticals to release Q3 and YTD 2024 financial results on Nov 14, 2024, followed by a conference call at 4:30pm ET.
quantisnow.com
·

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. Announce Signing ...

HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, signs LOI to acquire revenue-generating, EBITDA-positive Interventional Psychiatry Clinics in Florida, expected to be immediately accretive to both revenue and EBITDA.
globenewswire.com
·

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE

NRx Pharmaceuticals and HOPE Therapeutics to present at ThinkEquity Conference on Oct 30, 2024, in New York, featuring Jonathan Javitt, MD, MPH, and NRx management team.
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy